Role of Long non-coding RNAs among prostate cancer Patients

Abstract

Background: Long non-coding RNAs (lncRNAs) have recently been found to play a significant role in the development of some cancers. They are frequently involved in or caused by the progression of tumors when their dysregulation is present. Long non-coding RNAs (lncRNAs) have the potential to worsen castration resistance, cell proliferation, invasion, and metastasis in prostate cancer, the most prevalent cancer in men. As tumors grow, lncRNA expression patterns can shift, with some lncRNAs—like HOX transcript antisense RNA, or HOTAIR—constantly increasing and others—like downregulated RNA in cancer, or DRAIC—gradually decreasing. Like other cancers, prostate cancer lncRNAs serve as diagnostic tools (e.g., PCA3), prognostic tools (e.g., SChLAP1), and predictive tools (e.g., MALAT-1, metastasis-associated lung adenocarcinoma transcript). Because of their ever-changing function in prostate cancer, long non-coding RNAs (lncRNAs) have the potential to be therapeutic targets that aid in halting the progression of the illness, preventing metastasis, and preventing castration resistance.